Here's Why DaVita HealthCare (DVA) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
DaVita: International Expansion And Buybacks Will Boost Returns
International expansion continues with new clinics in Brazil, Ecuador, Chile, and Colombia, supporting long-term growth beyond the US market. DaVita's stock offers a 10% FCF yield, and the share count is decreasing at a fast pace. On top of share buybacks, the company will grow revenues above inflation due to its defensive business model and 35% market share.
Here's Why DaVita HealthCare (DVA) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why DaVita HealthCare (DVA) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
DaVita Stock Down Despite Q1 Earnings Beat, Margins Contract
Strength in revenue per treatment and dialysis patient service revenues drives DVA's first-quarter 2025 performance despite a year-over-year decline in normalized non-acquired treatment.
DaVita Inc. (DVA) Q1 2025 Earnings Call Transcript
DaVita Inc. (NYSE:DVA ) Q1 2025 Earnings Conference Call May 12, 2025 5:00 PM ET Company Participants Nic Eliason - Group VP, IR Javier Rodriguez - CEO Joel Ackerman - CFO Conference Call Participants Andrew Mok - Barclays Christian Porter - Bank of America Dean Rosales - Wolfe Research Pito Chickering - Deutsche Bank A.J. Rice - UBS Ryan Langston - TD Cowen Operator Good evening.
DaVita HealthCare (DVA) Q1 Earnings and Revenues Beat Estimates
DaVita HealthCare (DVA) came out with quarterly earnings of $2 per share, beating the Zacks Consensus Estimate of $1.75 per share. This compares to earnings of $2.38 per share a year ago.
DaVita First-Quarter 2025 Financial Results: Just the Numbers
Kidney treatment company DaVita (DVA) on Monday afternoon reported first-quarter 2025 financial results. A summary of its key numbers is below.
Can Revenue Cycle Operations Drive DVA Stock Before Q1 Earnings?
Continued strength in revenue cycle operations is likely to have boosted DaVita's top line in the first quarter despite supply challenges weighing on its performance.
DaVita HealthCare (DVA) Outperforms Broader Market: What You Need to Know
DaVita HealthCare (DVA) closed the most recent trading day at $143.96, moving +0.94% from the previous trading session.
DaVita HealthCare (DVA) Stock Falls Amid Market Uptick: What Investors Need to Know
DaVita HealthCare (DVA) closed at $140.44 in the latest trading session, marking a -0.78% move from the prior day.
DaVita HealthCare (DVA) Ascends But Remains Behind Market: Some Facts to Note
In the latest trading session, DaVita HealthCare (DVA) closed at $134.97, marking a +1.1% move from the previous day.
